Great Lakes NeuroTechnologies (GLNT) www.glneurotech.com has successfully transitioned their Kinesia technology for objective monitoring of Parkinson’s disease to an app platform. The app platform makes technology more accessible to individuals with Parkinson’s disease so that their symptoms can be assessed and improve their quality of life.
Kinesia ONE™ http://glneurotech.com/kinesia uses a patient worn sensor and iOS app to objectively measure Parkinson’s symptoms such as tremors, bradykinesia (slowed movements), and dyskinesia (involuntary movements). Cloud storage and a web app make symptom data and reports available to clinicians and researchers.
GLNT is strategically transitioning their Parkinson’s technology to app-based systems with Kinesia ONE marking the first step. The Kinesia technology is FDA cleared to market, CE marked, and is TGA and Health Canada approved.
“While Kinesia technology has been successfully integrated into a growing number of clinical trials by pharmaceutical and medical device manufacturers over the past year, accessibility has remained a barrier to wide scale adoption” reports Thomas Mera, Product Development Manager. “Expanding our Kinesia product portfolio to include app-based platforms significantly improves accessibility for individuals.”